Analyst Price Targets — KRRO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 19, 2026 10:06 am | Mitchell Kapoor | H.C. Wainwright | $15.00 | $9.97 | TheFly | Korro Bio price target lowered to $15 from $20 at H.C. Wainwright |
| March 13, 2026 11:27 am | Steve Seehouse | Cantor Fitzgerald | $22.00 | $11.50 | StreetInsider | Korro Bio (KRRO) PT Raised to $22 at Cantor Fitzgerald on UCD Potential |
| March 13, 2026 8:26 am | Ryan Deschner | Raymond James | $23.00 | $11.50 | StreetInsider | Raymond James Upgrades Korro Bio Inc. (KRRO) to Outperform |
| February 18, 2026 9:23 pm | — | Raymond James | $18.00 | $11.24 | StreetInsider | Clear Street Upgrades Korro Bio Inc. (KRRO) to Buy |
| January 29, 2026 11:08 am | — | H.C. Wainwright | $20.00 | $11.69 | TheFly | Korro Bio upgraded to Buy from Neutral at H.C. Wainwright |
| January 29, 2026 9:58 am | — | Chardan Capital | $15.00 | $11.69 | TheFly | Korro Bio upgraded to Buy from Neutral at Chardan |
| January 28, 2026 11:12 pm | Yasmeen Rahimi | Piper Sandler | $30.00 | $11.69 | TheFly | Korro Bio upgraded to Overweight from Neutral at Piper Sandler |
| January 28, 2026 12:09 pm | Myles Minter | William Blair | $10.00 | $11.17 | StreetInsider | William Blair Reiterates Market Perform Rating on Korro Bio Inc. (KRRO), 'early stages of its pipeline with clinical data unlikely until 2027' |
| January 28, 2026 11:54 am | — | Oppenheimer | $22.00 | $10.74 | TheFly | Korro Bio upgraded to Outperform from Perform at Oppenheimer |
| January 27, 2026 9:10 pm | Steve Seedhouse | Cantor Fitzgerald | $21.00 | $10.74 | TheFly | Korro Bio upgraded to Overweight from Neutral at Cantor Fitzgerald |
Latest News for KRRO
CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, President & Chief Executive Officer will participate in the following investor conferences:
Korro Bio, Inc. (NASDAQ: KRRO - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twelve analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, six have issued a buy recommendation and three have assigned a
CAMBRIDGE, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of a non-statutory stock option to one newly hired employee.
Korro Bio, Inc. (KRRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical trial in second half of 2026 Received Orphan Drug Designation from the European Medicines Agency (EMA) for KRRO-121 for patients with urea cycle disorders (UCDs) Nominated KRRO-111 as development candidate for the treatment of Alpha-1 Antitrypsin Deficiency (AATD); potential…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KRRO.
U.S. House Trading
No House trades found for KRRO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.